Ranbaxy Inc. Sustainability Profile
Ranbaxy Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States and operates extensively across North America, Europe, and Asia. Founded in 1961, the company has established itself as a leader in generic and specialty pharmaceuticals, focusing on high-quality, affordable medications that cater to diverse healthcare needs. With a robust portfolio that includes a wide range of generic drugs, Ranbaxy is renowned for its commitment to innovation and quality. The company has achieved significant milestones, including numerous FDA approvals and a strong presence in the global market. Its dedication to research and development sets it apart, ensuring that it remains at the forefront of the pharmaceutical sector. As a trusted name in healthcare, Ranbaxy Inc. continues to make strides in improving patient access to essential medications.
DitchCarbon Score
How does Ranbaxy Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ranbaxy Inc.'s score of 47 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Ranbaxy Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Sun Pharmaceutical Industries Limited, which may influence its climate commitments and emissions reporting. As of now, Ranbaxy Inc. has not established any documented reduction targets or specific climate pledges. The absence of emissions data and reduction initiatives suggests that the company may be in the early stages of developing its climate strategy or may rely on the broader commitments of its parent company. Given the lack of specific emissions figures, it is essential to note that any climate initiatives or targets would likely be aligned with those of Sun Pharmaceutical Industries Limited, from which emissions data and performance metrics may be cascaded. This relationship indicates that Ranbaxy Inc. could potentially adopt or adapt the sustainability practices and targets set by its parent organisation in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Scope 1 | 77,616,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 377,728,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | 000,000,000 | 000,000,000 |
How Carbon Intensive is Ranbaxy Inc.'s Industry?
How Carbon Intensive is Ranbaxy Inc.'s Location?
Ranbaxy Inc.'s Scope 3 Categories Breakdown
Ranbaxy Inc.'s Scope 3 emissions, which increased by 6% last year and increased by approximately 6% since 2023, demonstrating supply chain emissions tracking. Most of their carbon footprint comes from suppliers and value chain emissions, with Scope 3 emissions accounting for 51% of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 62% of Scope 3 emissions.
Top Scope 3 Categories
Ranbaxy Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Ranbaxy Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
